Searched for
DRL STOCK PRICE
Should you buy the dip? Strategist Anand James shares his weekly stock strategyMarket expert Anand James suggests caution following recent volatility. He notes the Nifty needs to break above 24,140 for a confirmed upsw...- Market Outlook: Rupak De’s top 3 trading stock picks for the week aheadGeopolitical tensions, rising crude oil, and a weakening rupee are fueling market volatility, according to Rupak De of LKP Securities. He n...
- Dr Reddy's shares rally 4% as Nuvama upgrades rating to buyDr. Reddy’s Laboratories shares rose 4% after Nuvama upgraded its rating to 'buy,' citing proactive strategies to mitigate the impact of Re...
- Dr Reddy’s shares tumble 5% as Q4 numbers fail to impress analysts. Should you buy, sell or hold?Dr Reddy’s Share Price: The company said that the jump in YoY net profit was largely driven by growth in global generics revenues in North ...
- Dr Reddy's tumbles 7% post Q4 results! Here's what brokerages recommendDr Reddy's Laboratories reported an 890% YoY surge in March quarter profit at Rs 960.1 crore but shares tumbled nearly 7% to Rs 4,545 in Th...
- Trader's Guide: 2 laregcap pharma stocks that can rise up to 5%This pharmaceutical stock is on the verge of a breakout from the technical price pattern of a symmetrical triangle. A close near the breako...
- Dr Reddy’s Q2 results: Consolidated PAT rises 30% YoY, beats estimateThe drugmaker reported an 18 per cent on-year rise in consolidated revenues to Rs. 5,763 crore for the reported quarter, which also beat St...
- Neutral on Dr. Reddy's Laboratories, target price Rs 5200: Motilal OswalDr. Reddy's Laboratories Ltd., incorporated in the year 1984, is a Large Cap company (having a market cap of Rs 80574.04 Crore) operating i...
- Dr Reddy's lines up Rs 1,000 crore capex for current fiscal yearThe Hyderabad based firm invested about Rs 1,000 crore in the 2020-21 fiscal year.
- Dr Reddy's strong product pipeline and other factors that make it stock pick of the weekDRL continues to generate free cash flows (FCFs) due to strongholds in some legacy drugs. Its lower valuation compared to its peers and str...
- How did India's Big Pharma fare in the December Quarter?Sun Pharma reported its highest-ever quarterly sales, and Cipla posted the highest-ever Ebitda margin in the company's recent history. Lupi...
- Elections results don’t matter much for pharma stocksThe sector has its own battles to fight – which are more regulatory, global and endemic in nature.
- Why investors should be more worried about Lupin than DRLMain focus area remains complex generics where other cos have an advantage
- DRL stock slips 5% after US court orderThe scrip was 5.30 per cent down at Rs 2,565.60 at around 02.12 pm.
- Dr Reddy’s, feeling the pain now, looks better from long-term viewThe 'sell' recommendations on the stock more than doubled from 7 to 17 with leading brokerages downgrading the stock.
- Brokerages raise price target on Dr Reddy's to as high as Rs 2,720 on FDA nodBrokerages see the FDA approval to Dr Reddy’s Laboratories (DRL) for generic Vidaza as a positive for the company.
- Growth in US, local market to pep up DRLDr Reddy’s Laboratories (DRL), India’s third-largest pharma company, has seen a sharp rise of 25% in its stock price over the past fifteen ...
- Analyst's Pick: Dr Reddy's LaboratoriesCitigroup recommends 'Hold' rating on Dr Reddy’s Laboratories with a target price of Rs 547.
- Overcharging drug cos may have to cough up huge finesDrug companies including Ranbaxy Laboratories, Dr Reddy’s Laboratories (DRL) and Lupin may have to pay over Rs 1,600 crore as penalties for...
- DRL net dips 68% on price pressure, writedownDr Reddy’s Laboratories (DRL) suffered a 68% fall in Q4 net profit ended March 2008, after writing down the intangible value of the product...
Load More
